Stem cell transplant for mantle cell lymphoma in Taiwan.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 04 2022
05 04 2022
Historique:
received:
29
10
2021
accepted:
17
03
2022
entrez:
6
4
2022
pubmed:
7
4
2022
medline:
8
4
2022
Statut:
epublish
Résumé
Mantle cell lymphoma (MCL) is a B-cell lymphoma featuring an aggressive course and a progressive relapsing pattern. International guidelines recommend early consolidative autologous stem cell transplant (auto-SCT) for eligible patients while reserving allogeneic SCT (allo-SCT) as therapy for refractory cases. Since data describing the implementation of transplants in the Asian population with MCL are limited, we aimed to analyze post-SCT outcomes of 99 MCL patients from the Taiwan Bone Marrow Transplant Registry database. The median age was 56 years, and 11% of the patients had blastoid variant MCL. Ninety-four patients received auto-SCT, while 13 patients received allo-SCT, eight of which received allo-SCT after failing auto-SCT. Before auto-SCT, 52% of the patients were in their first complete remission (CR1). Overall, 37 patients (39%) relapsed after auto-SCT. The median post-auto-SCT progression-free survival and overall survival (OS) were 43.6 months and not reached, respectively. Blastoid variant MCL, transplant not received in CR1, and disease progression within 12 months post-auto-SCT independently predicted inferior OS in multivariable analysis. The median post-allo-SCT OS was 74 months. Two patients (15%) died of MCL recurrence post-allo-SCT. Three patients with refractory diseases were salvaged with ibrutinib or venetoclax to allo-SCT. Treatment strategies incorporating novel agents warrant further optimization.
Identifiants
pubmed: 35383213
doi: 10.1038/s41598-022-09539-5
pii: 10.1038/s41598-022-09539-5
pmc: PMC8983774
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5662Informations de copyright
© 2022. The Author(s).
Références
Cancer. 2003 Feb 1;97(3):586-91
pubmed: 12548600
Blood. 2008 Jan 15;111(2):558-65
pubmed: 17962512
Ann Oncol. 2014 May;25(5):1053-8
pubmed: 24585719
J Clin Oncol. 2014 Feb 1;32(4):273-81
pubmed: 24344210
J Clin Oncol. 2016 Apr 20;34(12):1386-94
pubmed: 26926679
N Engl J Med. 2017 Sep 28;377(13):1250-1260
pubmed: 28953447
Br J Haematol. 2012 Aug;158(3):355-62
pubmed: 22640180
Br J Haematol. 2021 Apr;193(2):290-298
pubmed: 33620106
Ann Oncol. 2017 Jul 1;28(suppl_4):iv62-iv71
pubmed: 28881919
Leukemia. 2012 Jan;26(1):149-57
pubmed: 21799510
Br J Cancer. 2000 Jan;82(2):278-82
pubmed: 10646877
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Br J Haematol. 2015 Sep;170(5):657-68
pubmed: 25953436
Br J Haematol. 2016 Nov;175(3):410-418
pubmed: 27378674
Br J Haematol. 2019 Jun;185(5):940-944
pubmed: 30407625
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Oncol. 2016 Apr 10;34(11):1256-69
pubmed: 26755518
N Engl J Med. 2015 Mar 5;372(10):944-53
pubmed: 25738670
Br J Haematol. 2012 Feb;156(3):346-53
pubmed: 22145911
Lancet. 2016 Feb 20;387(10020):770-8
pubmed: 26673811
J Clin Pathol. 2006 Jul;59(7):780
pubmed: 16803955
J Clin Oncol. 2005 Oct 1;23(28):7013-23
pubmed: 16145068
J Hematol Oncol. 2020 Mar 17;13(1):21
pubmed: 32183871
Lancet. 2018 Feb 17;391(10121):659-667
pubmed: 29241979
N Engl J Med. 2018 Mar 29;378(13):1211-1223
pubmed: 29590547
Leukemia. 2015 Feb;29(2):464-73
pubmed: 25034148
Leukemia. 2021 Mar;35(3):787-795
pubmed: 32782382
N Engl J Med. 2013 Aug 8;369(6):507-16
pubmed: 23782157
Blood. 2018 Oct 18;132(16):1647-1656
pubmed: 30154113
Blood. 2013 Jan 3;121(1):48-53
pubmed: 22718839
N Engl J Med. 2012 Nov;367(18):1765; author reply 1765-6
pubmed: 23113500
Leukemia. 2002 Apr;16(4):587-93
pubmed: 11960337
Bone Marrow Transplant. 2020 Jun;55(6):1076-1084
pubmed: 31953532
J Clin Oncol. 2017 Mar 10;35(8):826-833
pubmed: 28095146
Blood Cancer J. 2019 May 20;9(6):50
pubmed: 31110172
Blood. 2014 Nov 6;124(19):3029-31
pubmed: 25377565
Ann Hematol. 2020 Feb;99(2):223-228
pubmed: 31853704
Eur J Cancer. 2016 Jul;62:132-7
pubmed: 27189322
Blood. 2018 Dec 27;132(26):2722-2729
pubmed: 30385481
Am J Hematol. 2017 Aug;92(8):806-813
pubmed: 28699667
Am J Hematol. 1998 Dec;59(4):295-301
pubmed: 9840910
Br J Haematol. 2019 Mar;184(6):1006-1010
pubmed: 30537212
Blood. 2017 Oct 26;130(17):1903-1910
pubmed: 28819011
Lancet Haematol. 2017 Jan;4(1):e2-e3
pubmed: 27927585
J Clin Oncol. 1995 Mar;13(3):588-95
pubmed: 7884420
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Blood. 2017 Oct 26;130(17):1876-1877
pubmed: 29074593
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Int J Hematol. 2018 Apr;107(4):420-427
pubmed: 29502313
Lancet Oncol. 2018 Nov;19(11):1449-1458
pubmed: 30348538
J Clin Oncol. 2011 Aug 1;29(22):3023-9
pubmed: 21730271
Blood. 2005 Apr 1;105(7):2677-84
pubmed: 15591112
N Engl J Med. 1993 Apr 8;328(14):1002-6
pubmed: 7680764
Br J Haematol. 2017 Nov;179(3):430-438
pubmed: 28832957
Am J Hematol. 2006 Aug;81(8):568-75
pubmed: 16823825
Am J Hematol. 2018 Oct;93(10):1220-1226
pubmed: 30033656
J Clin Oncol. 2005 Mar 20;23(9):1984-92
pubmed: 15668467
Br J Haematol. 2019 Mar;184(6):999-1005
pubmed: 30560573
Br J Haematol. 2018 Jul;182(1):46-62
pubmed: 29767454
Int J Hematol. 2020 Sep;112(3):385-394
pubmed: 32519171
Int J Hematol. 2011 May;93(5):684-686
pubmed: 21479980
Ann Hematol. 2015 Dec;94(12):2025-32
pubmed: 26411584
Lancet Haematol. 2017 Jan;4(1):e15-e23
pubmed: 27927586
Br J Haematol. 2016 Jan;172(1):80-8
pubmed: 26648336
Biol Blood Marrow Transplant. 2013 Apr;19(4):625-31
pubmed: 23333532
N Engl J Med. 2020 Apr 2;382(14):1331-1342
pubmed: 32242358
Cancer Res Treat. 2018 Jan;50(1):222-238
pubmed: 28361523
J Clin Oncol. 2013 Apr 10;31(11):1442-9
pubmed: 23401442